Drug-induced prolongation of the QT interval.
By D. Roden. New England Journal of Medicine, 2004
840 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/94f32103bbfbcbe9f02510685e8b02c24dcd4595
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- European Resuscitation Council Guidelines 2021: Epidemiology of cardiac arrest in Europe. (2021, background): “Data suggest that women are at higher risk for QT prolongation.(216,241)”
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “The QT interval is a surrogate marker for cardiac repolarisation abnormalities, with significant prolongation associated with the development of potentially lifethreatening ventricular arrhythmias such as torsade de pointes.(51) While QT interval prolongation is common in cancer patients, clinical e”
- Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death (2009, background): “Typical Acetophenazine (60), chlorpromazine (100), chlorprothixene (50), fluphenazine (2), haloperidol (2), loxapine (15), mesoridazine (50), molindone (10), perphenazine (10), pimozide (2), thioridazine (100), thiothixene (5) trifluoperazine (5), triflupromazine (25) 2.”
- ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, neutral): “Copyright © 2004 Massachusetts Medical Society (294).”